Physician profile
Robert M Najera
NPI 1891097689
$15,666.61
in general payments reported to CMS, 2019-2025
16 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $72.03 · 2021: $151 · 2022: $185 · 2023: $143 · 2024: $168 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $571.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $14,832.98 | 2019-2022 | |
| Abbvie INC. | $218.08 | 2023-2025 | |
| Motiva USA, LLC | $146.31 | 2025 | |
| Urovant Sciences INC | $86.30 | 2021-2022 | |
| Tepha INC | $75.13 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $72.92 | 2023 | Gemtesa |
| Boston Scientific Corporation | $38.11 | 2019-2024 | |
| Axonics, INC. | $34.66 | 2022-2024 | Bulkamid |
| Sientra, INC. | $32.33 | 2021 | |
| Davol INC. | $20.87 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.87 | 2023 | Exparel |
| Medline Industries Lp | $20.51 | 2024 | |
| Antares Pharma, INC. | $19.45 | 2021 | |
| Bluewind Medical | $18.96 | 2025 | Revi |
| Laborie Medical Technologies Corp. | $14.64 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $14.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Najera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.